Alembic Pharma’s Rhizen gets approval for oral Cancer drug.
This oral cancer drug was found after 08 years of extensive research. The best part of this drug is that it only attacks bad cells of the body, due to which the issue of hair loss leading to trauma is ruled out. Umbralisib (UKONIQTM) granted accelerated approval by US FDA for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL), follicular lymphoma (FL).Umbralisib, a novel next generation inhibitor of PI3K delta & CK1 epsilon, was discovered by Rhizen Pharmaceuticals and subsequently licensed to…
